Oral cancer is the sixth most common cancer in the world ([Nair *et al*, 1996](#bib28){ref-type="other"}), and was accounted to be the fifth leading cause of male cancer mortality in Taiwan in 2002 ([Department of Health, ROC, 2003](#bib9){ref-type="other"}). Epidemiological studies have clearly indicated that areca quid (AQ) chewing, cigarette smoking and alcohol are the major risk factors for oral squamous cell carcinoma (OSCC) ([IARC, 1985](#bib20){ref-type="other"}; [Ko *et al*, 1995](#bib22){ref-type="other"}). In Taiwan, approximately 80% of all oral cancer patients are associated with the AQ chewing habit ([Ko *et al*, 1995](#bib22){ref-type="other"}). In addition, most Taiwanese AQ chewers are also smokers and alcohol drinkers.

The p53 tumour suppressor protein is involved in cell-cycle control, apoptosis and DNA repair ([Vogelstein *et al*, 2000](#bib39){ref-type="other"}). The importance of the *p53* tumour suppressor gene in the process of carcinogenesis is well established ([Hussain and Harris, 1998](#bib19){ref-type="other"}). Mutation at *p53* has been demonstrated in over 50% of human cancers, especially tobacco-related cancers. Recently, we reported an important contributive role for tobacco carcinogens in *p53* mutation for a series of Taiwanese patients with OSCCs ([Hsieh *et al*, 2001](#bib18){ref-type="other"}). The most prevalent types of *p53* mutation found in Taiwanese OSCCs were G:C to A:T transitions and G:C to T:A transversions. Studies have demonstrated that these types of mutations are the most common mutations observed in animals treated with NNK or other tobacco nitrosamines ([Belinsky *et al*, 1991](#bib4){ref-type="other"}; [Oreffo *et al*, 1993](#bib29){ref-type="other"}; [Ronai *et al*, 1993](#bib30){ref-type="other"}; [Chang *et al*, 1996](#bib7){ref-type="other"}). Evidence from the literature also indicates that NNK-associated DNA adducts, in addition to being repaired by the nucleotide excision repair pathway, are also repaired by base excision repair ([Cloutier and Castonguay, 1998](#bib8){ref-type="other"}). *XRCC1* plays an important role in the base excision repair pathway, and interacts with DNA polymerase *β*, PARP and DNA ligase III. It also has a BRCT domain, which is characteristic of proteins involved in cycle checkpoint functions and this domain may be responsive to DNA damage ([Caldecott *et al*, 1996](#bib6){ref-type="other"}; [Masson *et al*, 1998](#bib24){ref-type="other"}). [Abdel-Rahman and El-Zein (2000)](#bib1){ref-type="other"} found that the 399*Gln* polymorphism of *XRCC1* appeared to be associated with reduced repair of NNK-induced genetic damage in cultured human lymphocytes. We found that OSCC patients with an *XRCC1* 399*Gln*/*Gln* genotype exhibited a significantly higher frequency of *p53* mutation than those with an *Arg*/*Gln* or an *Arg*/*Arg* genotype ([Hsieh *et al*, 2003](#bib16){ref-type="other"}).

It is known that one type of *p53* polymorphism that is found in the general population results in either an Arg or a Pro at residue 72 and this produces a marked change in the structure of the p53 protein ([Matlashewski *et al*, 1987](#bib25){ref-type="other"}). Recently, [Marin *et al* (2000)](#bib23){ref-type="other"} and [Tada *et al* (2001)](#bib37){ref-type="other"} have reported that the *Arg72* allele was preferentially mutated and retained in various human tumours. In addition to codon 72 polymorphism, [Wu *et al* (2002)](#bib40){ref-type="other"} found that cells with different *p53* haplotypes of exon 4--intron 3--intron 6 showed different capacities for DNA repair and apoptosis. In this study, we test whether different *p53* haplotypes of exon 4--intron 3--intron 6 would associate with *p53* mutations and examine the role of the *Arg72* allele in loss of heterozygosity (LOH) of *p53* gene in Taiwanese OSCCs.

MATERIALS AND METHODS
=====================

Patients, tissue specimens and clinical diagnosis
-------------------------------------------------

This study was approved by the Institutional Review Board, Chang Gung Memorial Hospital. A total of 715 OSCC patients treated at Chang Gung Memorial Hospital, Lin-Kuo during the period from March 1999 to December 2001 were recruited consecutively for participation in the present study. All cases were histologically confirmed. Female patients (*n*=42) were excluded from this study because of an insufficient number. Those who were diagnosed as nonsquamous cell carcinoma (*n*=44) were also excluded. Thus, a total of 629 male OSCC patients, including 237 patients previously studied ([Hsieh *et al*, 2003](#bib16){ref-type="other"}), were included for the present analysis. All patients gave informed consent for participation and were interviewed uniformly before surgery by a well-trained interviewer. The questionnaire used in the interview sought detailed information on current and past cigarette smoking, alcohol drinking and AQ chewing habits, occupational history, family disease history, dietary history and general demographic data.

For each case, two samples were taken, a tumour sample and a sample from the adjacent normal nontumour tissue. These samples were surgically dissected into small pieces, frozen immediately in liquid nitrogen and stored at −80°C. In addition, 10 ml of venous blood was drawn into heparinised tubes (Vacutainer) and stored at 4°C. The whole blood was separated into plasma, buffy coat cells and red blood cells by centrifugation within 18 h of obtaining the blood, and stored in a −80°C freezer. Genomic DNA for genotyping was extracted and purified from the buffy coat cells as previously described ([Hsieh *et al*, 2003](#bib16){ref-type="other"}).

The surgically removed samples were sent to the Department of Pathology, Chang Gung Medical Center for examination and scored according to the recommendations for the reporting of specimens containing oral cavity and oropharynx neoplasms by the [Associations of Directors of Anatomic and Surgical Pathology (ADASP) (2000)](#bib3){ref-type="other"}. Histology diagnosis was defined as squamous cell carcinoma, verrucous carcinoma, cylindric cell carcinoma, adenoid cystic carcinoma, mucoepidermoid carcinoma and adenocarcinoma.

As reference male controls, 371 subjects with available blood samples selected from 3000 random samples of the Taiwanese general population collected to study blood lead concentrations were included in this study ([Hsieh *et al*, 2000](#bib17){ref-type="other"}).

Tobacco, AQ and alcohol use
---------------------------

Study participants were asked if they had ever smoked cigarettes, chewed AQ or drank alcohol on a regular basis (at least once a week for 1 year). Those who responded 'yes\' to these questions were classified as tobacco, AQ and alcohol users, respectively.

*p53* genotype and haplotype determination
------------------------------------------

The genotype of *p53* for intron 3, exon 4 and intron 6 was determined by PCR-RFLP ([Wu *et al*, 2002](#bib40){ref-type="other"}) followed by polyacrylamide gel electrophoresis. For the exon 4 codon 72 polymorphism, a 396 bp DNA fragment was amplified and digested with *Bst*UI. The *Arg/Arg* homozygotes showed two bands of 165 and 231 bp, the *Arg/Pro* heterozygotes showed three bands of 165, 231 and 396 bp and the *Pro/Pro* homozygotes showed only one band of 396 bp. For the intron 3 polymorphism, either a 180 or 196 bp DNA fragment was amplified. The WW (without the 16 bp duplication) homozygotes showed one band of 180 bp, the WM heterozygotes showed two bands of 180 and 196 bp and the MM (with the 16 bp duplication) homozygotes showed only one band of 196 bp. For the intron 6 polymorphism, a 404 bp DNA fragment was amplified and digested with *Msp*I. The GG homozygotes showed two bands of 68 and 336 bp, the GA heterozygotes showed three bands of 68, 336 and 404 bp and the AA homozygotes showed only one band of 404 bp.

*p53* haplotypes could be inferred directly from the genotyping results for the individuals who were heterozygous at only one site or at no sites. For the other individuals, allele cloning and PCR-RFLP methods were used to determine the haplotypes. A 1.6 kb fragment of *p53* gene containing intron 3, exon 4 and intron 6 was amplified, cloned with the pCR® 2.1 vector (Invitrogen, Carlsbad, CA, USA) and transformed into INVαF′ cells. At least five white clones of each case were genotyped for intron 3, exon 4 and intron 6 by PCR-RFLP as described above.

Mutation and LOH analysis of the *p53* gene
-------------------------------------------

According to [Soussi and Beroud (2001)](#bib34){ref-type="other"}, 13.6% of *p53* mutations were located outside exons 5--8, with a significant number of mutations in exons 4, 10 and, to a lesser extent, 9. Therefore, single-stranded conformation polymorphism (SSCP) analysis was used to analyse tumour samples for mutations within exons 4--10 of the *p53* gene. The lengths of PCR fragments for our SSCP analysis were in the range of 135--245 bp and the sensitivity and specificity of this technique to detect mutations even if only present in a low amount is more than 90%. Cases displaying an altered electrophoretic mobility were reamplified in another reaction and analysed by direct sequencing of both strands to confirm and characterise the nature of the mutation ([Hsieh *et al*, 2001](#bib18){ref-type="other"}).

For individuals who were heterozygous at exon 4 codon 72, DNA from their tumour tissues was used to amplify the 396 bp exon 4 fragment, which was digested with *Bst*UI, purified and analysed by denaturing high-performance liquid chromatography (DHPLC) (WAVE DNA Fragment Analysis System, Omaha, NE, USA) ([Kleymenova and Walker, 2001](#bib21){ref-type="other"}). PCR was performed for 27 cycles so that the reaction was still in the exponential phase of amplification. Then, DHPLC analysis was performed at 50°C and flow rate 0.9 ml min^−1^ in a gradient of acetonitrile in 0.1 [M]{.smallcaps} triethylammonium acetate: the gradient started at 8.75%, increased in 3.5 min to 13.75%, then increased in 7 min to 16.25%, was constant for 1 min, then increased in 1 min to 75%, was constant for 1 min (wash), then decreased in 1 min to 8.75% and finally was constant for 1 min (equilibration). The ratio of the peak area between the 396 bp fragment, the Pro allele, and the 231 bp fragment, the Arg allele, was calculated. Tumour DNA with a ratio outside the 95% confidence interval (CI) of the mean ratio from 30 normal controls was considered as positive for LOH in the *p53* gene (representative results by DHPLC are shown in [Figure 1](#fig1){ref-type="fig"}).

STATISTICAL ANALYSIS
====================

Statistical analyses were performed with the Statistical Analysis System (SAS) version 8.1. The association between the frequency of *p53* mutation or LOH and genotype/haplotype of *p53* intron 3, exon 4 and intron 6 was examined by *χ*^2^ or Fisher\'s exact test. Multiple logistic regression model was further used to assess the major factors attributed to the frequency of *p53* mutation.

RESULTS
=======

A total of 629 consecutive patients with a diagnosis of OSCC were enrolled in the study. The demographic information of the patients is shown in [Table 1](#tbl1){ref-type="table"}. The most common primary sites were the bucca and the tongue. In all, 94% (591/628) of the patients had smoked at some time, 62.4% (389/623) were users of alcohol at some time and 90.8% (570/628) had chewed AQ at some time.

As shown in [Table 2](#tbl2){ref-type="table"}, the frequencies of *Arg*72, W allele of intron 3 and G allele of intron 6 were 0.58, 0.97 and 0.97, respectively, in the referent male controls. The frequencies of the *Arg/Arg*, *Arg/Pro* and *Pro/Pro* genotypes for codon 72 were 34.50, 47.71 and 17.79%, respectively. The frequencies of the WW, WM and MM genotypes for intron 3 were 94.07, 5.39 and 0.54%, respectively. The frequencies of the GG, GA and AA genotypes for intron 6 were 94.07, 5.39 and 0.54%, respectively. All of the distributions were in Hardy--Weinberg equilibrium. The most common two haplotypes of exon 4--intron 3--intron 6 were Arg-W-G (58.36%), followed by Pro-W-G (38.41%). All other types were relatively rare. It is interesting to note that these rare haplotypes were slightly associated with a risk of oral cancer (odds ratio (OR)=1.72; 95% CI, 0.97--3.07).

Tumour samples from 272 OSCC patients without antecedent treatment, including 237 cases published previously ([Hsieh *et al*, 2001](#bib18){ref-type="other"}), were examined for mutations within exons 4--10 of the *p53* gene by PCR-SSCP. Based on [Table 2](#tbl2){ref-type="table"}, the associations between the common haplotypes of *p53* gene and cancer risk were slightly different in different sites of oral cancer (oral cavity cancer *vs* hypopharyngeal/oropharyngeal cancer). The cases of hypopharyngeal and oropharyngeal cancer were excluded for statistical analysis (*n*=18). Of the 254 oral cavity OSCCs, 128 (50.4%) showed a *p53* gene mutation at exons 4--10. Individuals with either one or no Pro-W-G alleles were more likely to have *p53* gene mutations (OR=1.99; 95% CI, 1.08--3.68; [Table 3](#tbl3){ref-type="table"}) than those with two Pro-W-G alleles. After adjustment for age, cigarette smoking, alcohol drinking, AQ chewing and *XRCC1* 399*Gln* polymorphism, individuals with one or no Pro-W-G alleles still had a higher frequency of *p53* mutations (OR=1.98; 95% CI, 1.10--3.56) than those with two Pro-W-G alleles.

Among the 128 OSCCs with *p53* mutations by SSCP, 12 samples contained two different mutations of the *p53* gene and 15 samples were not successfully sequenced. To reduce the complexity of interpretation, cases with two mutations were excluded from further analysis. Among the 101 mutations with an identified sequence, 16 (15.8%) were deletions or insertions, 53 (52.5%) were G:C to A:T transitions and 17 (16.8%) were G:C to T:A transversions. The forms of mutation were not significantly different between individuals with two Pro-W-G alleles and those with either one or no Pro-W-G alleles (data not shown).

Tumour samples from 172 informative male oral cavity cancer patients for *p53* gene exon 4 were examined for LOH of the *p53* gene. Of the 172 OSCCs, 72 (41.9%) showed LOH ([Table 4](#tbl4){ref-type="table"}). Among the 72 OSCCs with LOH of the *p53* gene, Pro allele loss was found in 53 (73.6%) of the tumours. The frequency of LOH of *p53* was not associated with age, cigarette smoking, AQ chewing or alcohol drinking. However, stage IV tumours had a slightly higher frequency (33/66, 50.0%) of *p53* LOH than stage I--III tumours (39/106, 36.8%) (*P*=0.09 by *χ*^2^). It is also interesting to note that alcohol drinking would seem to increase the frequency of *Arg* allele loss (OR=10.56; 95% CI, 1.23--234.94) among cigarette smokers and AQ chewers.

The status of *p53* gene mutation was known for 94 tumour samples from 172 informative male oral cavity cancer patients for *p53* gene exon 4. Of the 94 OSCCs, 67 (71.3%) showed alterations (mutation, LOH or both) of *p53* gene ([Table 5](#tbl5){ref-type="table"}). The frequency of LOH of *p53* was not different between 46 *p53*-mutated OSCCs and 48 *p53*-normal OSCCs (52.2 *vs* 43.8%, *P*=0.41 by *χ*^2^). However, LOH was more likely to appear at late than early tumour stage (14 events for stage IV *vs* seven events for stage I--III), while mutation occurred at the early tumour stage (16 events for stage I--III *vs* six events for stage IV). Therefore, stage IV tumours had a slightly higher frequency (26/45, 57.8%) of *p53* LOH than stage I--III tumours (19/49, 38.8%) (*P*=0.07 by *χ*^2^). Furthermore, a significant cumulative effect of mutation of *p53* and tumour stage on LOH of *p53* was observed (*P*=0.03 by *χ*^2^ trend test). It is also interesting to note that stage IV tumours had a slightly higher frequency (20/26, 76.9%) of *Pro* allele loss than stage I--III tumours (11/19, 57.9%) (*P*=0.17 by *χ*^2^) regardless of *p53* mutation. The frequency of *p53* mutation was not different between 31 OSCCs having *Pro* allele loss and 14 OSCCs with *Arg* allele loss (51.6 *vs* 57.1%, *P*=0.73 by *χ*^2^).

DISCUSSION
==========

p53 has a critical role in cell-cycle control, apoptosis and DNA repair ([Vogelstein *et al*, 2000](#bib39){ref-type="other"}). Among the more than 10 DNA sequence polymorphisms identified, the codon 72 polymorphism (Arg/Pro) has been explored in depth for a potential association with cancer. Although this polymorphism has been implied to be associated with certain cancer types ([Yu *et al*, 1999](#bib41){ref-type="other"}; [Fan *et al*, 2000](#bib11){ref-type="other"}; [Shepherd *et al*, 2000](#bib33){ref-type="other"}), [Sun *et al* (1999)](#bib36){ref-type="other"} reviewed 31 epidemiological case--control studies and suggested that codon 72 allelism did not have an impact on human cancer risk. The present study found that there was no significant difference in the frequency of codon 72 genotype between patients and referent controls (*P*=0.27). Recently, five case--control studies have been conducted to investigate an association between the *p53* codon 72 polymorphism and the risk of squamous cell carcinoma of the head and neck (SCCHN), but none of them have found a positive association ([Hamel *et al*, 2000](#bib15){ref-type="other"}; [McWilliams *et al*, 2000](#bib26){ref-type="other"}; [Summersgill *et al*, 2000](#bib35){ref-type="other"}; [Shen *et al*, 2002](#bib32){ref-type="other"}; [Mitra *et al*, 2003](#bib27){ref-type="other"}). Taken together, these results suggested that codon 72 allelism does not seem to have an impact on human cancer risk, especially for SCCHN, although [Dumont *et al* (2003)](#bib10){ref-type="other"} had demonstrated that the Arg72 form of p53 was at least five times better at inducing apoptosis than the Pro72 variant.

The difference in overall haplotype frequency between patients and referent controls was not significant in the present study (*P*=0.22). However, it is interesting to note that the rare haplotypes (rare allele in introns 3 and 6) were slightly associated with a risk of oral cancer (OR=1.72; 95% CI, 0.97--3.07) ([Table 2](#tbl2){ref-type="table"}). Recently, [Gemignani *et al* (2004)](#bib13){ref-type="other"} have observed that a rare allele in intron 3 was associated with an increased risk of colorectal cancer and reduced basal levels of *p53* mRNA in immortalised lymphoblastoid cell lines. Taken together, these results could support the speculation by [Wu *et al* (2002)](#bib40){ref-type="other"} that introns 3 and 6 rare alleles might exert a functional effect, because as the copy number of the rare allele in introns 3 and 6 is increased, the level of the apoptotic index is decreased.

In Taiwan, most of male oral cavity cancer patients have a history of both habitual cigarette smoking and AQ chewing. In the present study, among 167 male OSCC patients informative for *p53* gene exon 4, 141 (84.4%) have a history of both habitual cigarette smoking and AQ chewing. Among these 141 OSCC patients, 91 (64.5%) patients also had a history of habitual alcohol drinking. The frequency of LOH for *p53* did not differ between patients with and without alcohol drinking. However, interestingly, almost all of the patients (95.5%, 21/22) without alcohol drinking had lost the *Pro* allele, whereas only 68.4% (26/38) of the patients with alcohol drinking had lost the *Pro* allele. In this study, we did not determine which allele was mutated in the *p53*-mutated oral cavity cancer patients with germline heterozygosity (*Arg/Pro*). Further studies to determine the biological mechanism by which there is selection for different codon 72 alleles by alcohol drinking are thus desirable.

In the present study, we found that OSCC patients with the *Arg*72 allele had a significantly higher frequency of *p53* mutation than those with *Pro/Pro* genotype among patients with common alleles of introns 3 and 6 (OR=1.93; 95% CI, 1.03--3.63). In addition, 73.6% (53/72) of those who showed LOH of the *p53* gene had lost the *Pro* allele. These results are consistent with those reported by other authors for some tumour types, in which it has been pointed out that LOH of *p53* occurs more commonly for the *Pro* allele and that there is a preferential mutation of the *Arg*72 allele ([Brooks *et al*, 2000](#bib5){ref-type="other"}; [Marin *et al*, 2000](#bib23){ref-type="other"}; [Tada *et al*, 2001](#bib37){ref-type="other"}; [Furihata *et al*, 2002](#bib12){ref-type="other"}; [Anzola *et al*, 2003](#bib2){ref-type="other"}). Based on the reports assigning a higher apoptotic potential to the *Arg* allele ([Wu *et al*, 2002](#bib40){ref-type="other"}) and the current data, we could hypothesise that the cells carrying an *Arg* allele require further *p53* mutations to increase their tumorigenic potential, while *Pro/Pro* cells could undergo this procedure with fewer damage. Indeed, [Marin *et al* (2000)](#bib23){ref-type="other"} and [Tada *et al* (2001)](#bib37){ref-type="other"} found that the p53 mutant acts as a more potent inhibitor of p73 activity when p53 has *Arg*72 rather than *Pro*72. Additional comprehensive studies using this series of samples will be needed to elucidate the association between polymorphisms within *p53* and the mutant behaviour of *p53* in OSCCs associated with cigarette smoking, AQ chewing and alcohol drinking.

The two-hit paradigm of tumour suppressor gene mutation has held sway for many years. Recently, [Venkatachalam *et al* (1998)](#bib38){ref-type="other"} found that a high proportion of the tumours from the *p53*+/− mice retained an intact, functional, wild-type allele. This result indicates that mere reduction in p53 levels may be sufficient to promote tumorigenesis. Although *p53* mutation accompanied by complete loss of the wild-type allele is the most frequent event observed in many human cancers ([Greenblatt *et al*, 1994](#bib14){ref-type="other"}), we found no preference of mutation with LOH (*n*=24), mutation without LOH (*n*=22) or LOH without mutation (*n*=21) in 94 Taiwanese OSCCs with germline heterozygosity in codon 72 (*Arg/Pro*). Furthermore, LOH was more likely to appear at late than early tumour stage (14 for stage IV *vs* seven for stage I--III), while mutation was occurred at the early tumour stage (16 for stage I--III *vs* six for stage IV). These results support the hypothesis that haploinsufficiency of *p53* is in itself likely to contribute to tumour progression and the mutant form of *p53* has a dominant gain-of-function activity or it may block the wild-type protein by acting as a dominant negative ([Santarosa and Ashworth, 2004](#bib31){ref-type="other"}).

In conclusion, we found that *p53* codon 72 polymorphism may not be a dominant factor for predisposition to OSCCs in Taiwan. However, the present study revealed that (a) the Arg allele is associated with *p53* mutations, (b) the Pro allele is preferentially lost in OSCCs associated with cigarette smoking and AQ chewing, while the frequency of Arg allele loss is increased with alcohol drinking, and (c) haploinsufficiency of *p53* is in itself likely to contribute to tumour progression in Taiwanese OSCCs.
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###### 

Characteristics of the male patients with OSCCs (*n*=629)

  ------------------------------------------ -------------
  Age (years)                                 
   Mean±s.d.                                 49.93±10.67
   Range                                     25--78
                                              
  Site of primary tumour (*N* (%))            
   Oral cavity                               523 (83.2)
    Lip                                      19 (3.0)
    Tongue                                   175 (27.8)
    Mouth floor                              22 (3.5)
    Buccal mucosa                            208 (33.1)
    Gingiva                                  53 (8.4)
    Hard palate                              13 (2.1)
    Retromolar trigone                       33 (5.2)
   Oropharynx                                49 (7.8)
   Hypopharynx                               57 (9.1)
                                              
  Clinical stage (*N* (%))                    
   Stage I                                   79 (12.8)
   Stage II                                  136 (22.1)
   Stage III                                 125 (20.3)
   Stage IV                                  275 (44.7)
                                              
  Cigarette smoker at some time (*N* (%))    591 (94.1)
  Alcohol drinker at some time (*N* (%))     389 (62.4)
  Areca quid chewer at some time (*N* (%))   570 (90.8)
  ------------------------------------------ -------------

###### 

Risk estimates for *p53* haplotypes in male OSCC patients and control subjects

  --
  --

^a^Other OSCC patients: including oropharynx and hypopharynx cancer patients.

^b^W: common allele (without replicative 16 bp); M : rare allele (with replicative 16 bp).

###### 

Association of *p53* haplotypes and *p53* gene mutations in oral cavity cancer

  --
  --

^a^Adjusted for age, cigarette smoking, alcohol drinking, AQ chewing and XRCC1 399Gln polymorphism.

###### 

Stratification analysis of the risk factors for oral cavity cancer and the frequency of LOH of the *p53* gene

  --
  --

###### 

Association of mutation of *p53*, tumour stage and the frequency of LOH of the *p53* gene in oral cavity cancer

  **Mutation of *p53***    **Tumour stage**   **LOH/informative cases (%)**   **OR (95% CI)^\*^**   **Lost Pro allele/LOH cases (%)**    **OR (95% CI)**
  ----------------------- ------------------ ------------------------------- --------------------- ----------------------------------- --------------------
  No                            I--III                 7/21 (33.3)                     1                       4/7 (57.1)                       1
  Yes                           I--III                12/28 (42.9)             1.50 (0.40--5.75)               7/12 (58.3)                       
  No                              IV                  14/27 (51.0)             2.15 (0.57--8.35)              11/14 (78.6)              2.42 (0.56--10.77)
  Yes                             IV                  12/18 (66.7)            4.00 (0.88--19.32)               9/12 (75.0)                       
  Total                                               45/94 (47.9)                                            31/45 (68.9)                       

*P*=0.03 by *χ*^2^ trend test.
